SMN1: Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: SMN1

NCBI ID: G6606

SMN1

SMN1: Potential Drug Target and Biomarker for Neurodegenerative Diseases

SMN1 (SMN1 gene), also known as BCD541, is a protein that is expressed in the brain and is a key component of the survival motor neuron (SMN) gene family. SMN genes are responsible for producing a protein called survival motor neuron (SMN) protein, which is essential for the survival of nerve cells. The SMN1 gene is one of the four known SMN genes and is responsible for producing the SMN protein that is critical for the survival of nerve cells.

SMN1 is a 191 amino acid long protein that contains several important functions. It is the protein that is synthesized from the SMN2 gene and is responsible for maintaining the stability of the SMN protein. The SMN protein is composed of two distinct subunits, alpha and beta subunits. The alpha subunit is responsible for the structural integrity of the protein, while the beta subunit is responsible for its function.

SMN1 is known as a protein that is expressed in the brain and is involved in the development and maintenance of neural circuits. It is also involved in the regulation of neural circuits and is thought to play a role in the development of neurodegenerative diseases.

SMN1 has also been identified as a potential drug target and biomarker for several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

One of the main reasons for the potential of SMN1 as a drug target is its involvement in the development and maintenance of neural circuits. Neural circuits are critical for the proper functioning of the brain and are vulnerable to damage. SMN1 is involved in the regulation of neural circuits and has been shown to play a role in the development and maintenance of neural circuits in the brain.

SMN1 has also been shown to be involved in the regulation of gene expression in the brain. Studies have shown that SMN1 can interact with several transcription factors, including DNMT1, to regulate the expression of genes that are important for neural circuit development and function.

SMN1 has also been shown to play a role in the development and progression of neurodegenerative diseases. Studies have shown that SMN1 is expressed in the brains of individuals with Alzheimer's disease and that its levels are decreased in individuals with Parkinson's disease. Additionally, SMN1 has been shown to be involved in the development and progression of Huntington's disease, a genetic disorder that is characterized by the progressive loss of motor neurons.

SMN1 has also been identified as a potential biomarker for several neurodegenerative diseases. Studies have shown that SMN1 levels are decreased in individuals with Alzheimer's disease and that they are elevated in individuals with Parkinson's disease. Additionally, SMN1 has been shown to be decreased in individuals with Huntington's disease, a genetic disorder that is characterized by the progressive loss of motor neurons.

In conclusion, SMN1 is a protein that is expressed in the brain and is involved in the development and maintenance of neural circuits. It is also involved in the regulation of neural circuits and has been shown to play a role in the development and progression of neurodegenerative diseases. As a result, SMN1 is a potential drug target and biomarker for several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Further research is needed to fully understand the role of SMN1 in these diseases and to develop effective treatments.

Protein Name: Survival Of Motor Neuron 1, Telomeric

Functions: The SMN complex catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome, and thereby plays an important role in the splicing of cellular pre-mRNAs (PubMed:9845364, PubMed:18984161). Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP (Sm core) (PubMed:18984161). In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP (PubMed:18984161). To assemble core snRNPs, the SMN complex accepts the trapped 5Sm proteins from CLNS1A forming an intermediate (PubMed:18984161). Within the SMN complex, SMN1 acts as a structural backbone and together with GEMIN2 it gathers the Sm complex subunits (PubMed:21816274, PubMed:22101937, PubMed:17178713). Binding of snRNA inside 5Sm ultimately triggers eviction of the SMN complex, thereby allowing binding of SNRPD3 and SNRPB to complete assembly of the core snRNP (PubMed:31799625). Ensures the correct splicing of U12 intron-containing genes that may be important for normal motor and proprioceptive neurons development (PubMed:23063131). Also required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination (PubMed:26700805). May also play a role in the metabolism of small nucleolar ribonucleoprotein (snoRNPs)

The "SMN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets